Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

India’s IPA Sees No Imminent Coronavirus Shortages

Welcomes Initiatives To Promote Domestic Manufacturing Of APIs And KSMs

Executive Summary

The Indian Pharmaceutical Alliance is working closely with the World Health Organization and International Generic and Biosimilar Medicines Association, as well as regional off-patent industry bodies in the US and Europe, to “navigate challenges on the manufacturing and logistics front” due to the coronavirus pandemic. Meanwhile, the IPA has welcomed domestic initiatives to boost API manufacturing.

You may also be interested in...



India Approves 16 Applications Under PLI Scheme

India has approved a $46m project by giving the green light to 16 drug production applications under the Production Linked Incentive scheme. The government has ordered the setting up and commercial production of the 16 projects to commence immediately. 

Natco Settles Over Canadian Revlimid Rival

India’s Natco has struck a deal with Celgene to settle litigation over its proposed generic lenalidomide rival to Revlimid in Canada. News of the settlement came shortly after the Indian firm reported a decline in quarterly and annual revenues following supply chain disruptions caused by the coronavirus crisis.

Indian API Firms Buoyant But Big Generics Firms See US-Led Swings

Leading Indian API firms are on a firm earnings footing and the evolving dynamics amid COVID-19 augur well for the segment, a new study by an Indian firm indicates, but notes that large cap generic firms in the country have seen sharp revenue growth swings over the decade.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

GB149749

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel